157 related articles for article (PubMed ID: 25485173)
21. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
Raimbault A; Itzykson R; Willems L; Rousseau A; Chapuis N; Mathis S; Clauser S; Radford-Weiss I; Bouscary D; Fontenay M; Kosmider O; Bardet V
Cytometry B Clin Cytom; 2019 May; 96(3):215-222. PubMed ID: 30963682
[TBL] [Abstract][Full Text] [Related]
22. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.
Wang C; Kane R; Levenson M; Kelman J; Wernecke M; Lee JY; Kozlowski S; Dekmezian C; Zhang Z; Thompson A; Smith K; Wu YT; Wei Y; Chillarige Y; Ryan Q; Worrall C; MaCurdy TE; Graham DJ
JAMA Intern Med; 2016 Dec; 176(12):1818-1825. PubMed ID: 27775769
[TBL] [Abstract][Full Text] [Related]
23. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.
Stroupe KT; Tarlov E; Lee TA; Weichle TW; Zhang QL; Michaelis LC; Ozer H; Durazo-Arvizu R; Browning MM; Hynes DM
Pharmacotherapy; 2012 Nov; 32(11):988-97. PubMed ID: 23108695
[TBL] [Abstract][Full Text] [Related]
24. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
[TBL] [Abstract][Full Text] [Related]
25. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
Park S; Kelaidi C; Sapena R; Vassilieff D; Beyne-Rauzy O; Coiteux V; Vey N; Ravoet C; Cheze S; Rose C; Legros L; Stamatoullas A; Escoffre-Barbe M; Guerci A; Chaury MP; Fenaux P; Dreyfus F
Leuk Res; 2010 Nov; 34(11):1430-6. PubMed ID: 20580086
[TBL] [Abstract][Full Text] [Related]
26. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
Santini V
Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
[TBL] [Abstract][Full Text] [Related]
29. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.
Garelius HK; Johnston WT; Smith AG; Park S; de Swart L; Fenaux P; Symeonidis A; Sanz G; Čermák J; Stauder R; Malcovati L; Mittelman M; van de Loosdrecht AA; van Marrewijk CJ; Bowen D; Crouch S; de Witte TJ; Hellström-Lindberg E
J Intern Med; 2017 Mar; 281(3):284-299. PubMed ID: 27926979
[TBL] [Abstract][Full Text] [Related]
30. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
[TBL] [Abstract][Full Text] [Related]
31. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
32. Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer.
Du XL; Zhang Y
Clin Colorectal Cancer; 2015 Dec; 14(4):e21-31. PubMed ID: 26119923
[TBL] [Abstract][Full Text] [Related]
33. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
34. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
[TBL] [Abstract][Full Text] [Related]
35. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
37. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
38. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Buccisano F; Piccioni AL; Nobile C; Criscuolo M; Niscola P; Tatarelli C; Fianchi L; Villivà N; Neri B; Carmosino I; Gumenyuk S; Mancini S; Voso MT; Maurillo L; Breccia M; Zini G; Venditti A; Fenu S; Spiriti MA; Latagliata R;
Ann Hematol; 2016 Jun; 95(7):1059-65. PubMed ID: 27091349
[TBL] [Abstract][Full Text] [Related]
39. The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy.
Boone JD; Fauci JM; Walters CL; Whitworth JM; Bevis KS; Alvarez RD
Int J Gynecol Cancer; 2013 Feb; 23(2):367-71. PubMed ID: 23266649
[TBL] [Abstract][Full Text] [Related]
40. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
